Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

SAC Members and Research MD, PHD LaetitiaMichou Dr. Michou has completed her medicine studies at the University of Angers (France), her Rheumatology residency at the Denis Diderot-Paris VII University (France) […]

Available Volunteer Opportunities Call for Nominations – Board of Directors After evaluating the strengths of the existing Board of Directors, the Board Development Committee is seeking individuals with the following […]

Today, most people consume too much protein at dinner and not enough at breakfast. In recent years, scientific studies have shown that a balanced consumption of protein throughout the day […]

It is well known that calcium is a necessary nutrient because it plays an essential role in human health, not only for bone development but also for the heart, muscle […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

Our Senior Team Dr. Famida Jiwa President and CEO Dr. Jiwa is the President and CEO of Osteoporosis Canada, and has been with the organization since 2006. Prior to joining […]

Board of Directors Jeannette Briggs Chair | Oakville, ON Jeannette has more than 25 years of experience working in the energy sector.  She has held a wide-range of jobs within […]

Research Competition The Osteoporosis Research Program provides training awards to support Canadian investigators conducting research that promises to yield new insights into the prevention and treatment of osteoporosis and improving […]